Advertisement

Molecular Medicine

, Volume 23, Issue 1, pp 120–133 | Cite as

Nicotinic Acetylcholine Receptor-Mediated Protection of the Rat Heart Exposed to Ischemia Reperfusion

  • Spyros A. Mavropoulos
  • Nayaab S. Khan
  • Asaph C. J. Levy
  • Bradley T. Faliks
  • Cristina P. Sison
  • Valentin A. Pavlov
  • Youhua Zhang
  • Kaie Ojamaa
Research Article

Abstract

Reperfusion injury following acute myocardial infarction is associated with significant morbidity. Activation of neuronal or non-neuronal cholinergic pathways in the heart has been shown to reduce ischemic injury, and this effect has been attributed primarily to muscarinic acetylcholine receptors. In contrast, the role of nicotinic receptors, specifically α-7 subtype (α7nAChR), in the myocardium remains unknown, which offers an opportunity to potentially repurpose several agonists/modulators that are currently under development for neurologic indications. Treatment of ex vivo and in vivo rat models of cardiac ischemia/reperfusion (I/R) with a selective α7nAChR agonist (GTS21) showed significant increases in left ventricular developing pressure and rates of pressure development, without effects on heart rate. These positive functional effects were blocked by co-administration with methyllycaconitine (MLA), a selective antagonist of α7nAChRs. In vivo, delivery of GTS21 at the initiation of reperfusion reduced infarct size by 42% (p < 0.01) and decreased tissue reactive oxygen species (ROS) by 62% (p < 0.01). Flow cytometry of MitoTracker Red-stained mitochondria showed that mitochondrial membrane potential was normalized in mitochondria isolated from GTS21-treated compared with untreated I/R hearts. Intracellular adenosine triphosphate (ATP) concentration in cultured cardiomyocytes exposed to hypoxia/reoxygenation was reduced (p < 0.001), but significantly increased to normoxic levels with GTS21 treatment, which was abrogated by MLA pretreatment. Activation of stress-activated kinases JNK and p38MAPK was significantly reduced by GTS21 in I/R. We conclude that targeting myocardial α7nAChRs in I/R may provide therapeutic benefit by improving cardiac contractile function through a mechanism that preserves mitochondrial membrane potential, maintains intracellular ATP and reduces ROS generation, thus limiting infarct size.

Notes

Acknowledgments

The authors thank Seungjun Ahn, MS (Biostatistics Unit, The Feinstein Institute for Medical Research), for assistance with statistical analysis.

References

  1. 1.
    Batulevicius D, Frese T, Peschke E, Pauza DH, Batuleviciene V. (2013) Remodelling of the intracardiac ganglia in diabetic Goto-Kakizaki rats: an anatomical study. Cardiovasc. Diabetol. 12:85.CrossRefGoogle Scholar
  2. 2.
    Brodde OE, Bruck H, Leineweber K, Seyfarth T. (2001) Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res. Cardiol. 96:528–38.CrossRefGoogle Scholar
  3. 3.
    Calvillo L, et al. (2011) Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial ischemia and reperfusion. J. Cardiovasc. Pharmacol. 58:500–07.CrossRefGoogle Scholar
  4. 4.
    Davidson MM, et al. (2005) Novel cell lines derived from adult human ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 39:133–47.CrossRefGoogle Scholar
  5. 5.
    De Ferrari GM, et al. (2011) Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur. Heart J. 32:847–55.CrossRefGoogle Scholar
  6. 6.
    de Jonge WJ, et al. (2005) Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat. Immunol. 6:844–51.CrossRefGoogle Scholar
  7. 7.
    De Meersman RE, Stein PK. (2007) Vagal modulation and aging. Biol. Psychol. 74:165–73.CrossRefGoogle Scholar
  8. 8.
    Delfiner MS, Siano J, Li Y, Dedkov EI, Zhang Y. (2016) Reduced epicardial vagal nerve density and impaired vagal control in a rat myocardial infarction-heart failure model. Cardiovasc. Pathol. 26:21–9.CrossRefGoogle Scholar
  9. 9.
    Duprez DA. (2008) Cardiac autonomic imbalance in pre-hypertension and in a family history of hypertension. J. Am. Coll. Cardiol. 51:1902–03.CrossRefGoogle Scholar
  10. 10.
    Dvorakova M, et al. (2005) Developmental changes in the expression of nicotinic acetylcholine receptor alpha-subunits in the rat heart. Cell Tissue Res. 319:201–09.CrossRefGoogle Scholar
  11. 11.
    Gergalova G, et al. (2012) Mitochondria express alpha7 nicotinic acetylcholine receptors to regulate Ca2+ accumulation and cytochrome c release: study on isolated mitochondria. PloS One. 7:e31361.CrossRefGoogle Scholar
  12. 12.
    Gergalova G, Lykhmus O, Komisarenko S, Skok M. (2014) Alpha7 nicotinic acetylcholine receptors control cytochrome c release from isolated mitochondria through kinase-mediated pathways. Int. J. Biochem. Cell Biol. 49:26–31.CrossRefGoogle Scholar
  13. 13.
    Handa T, et al. (2009) Anti-Alzheimer’s drug donepezil markedly improves long-term survival after chronic heart failure in mice. J. Card. Fail. 15:805–11.CrossRefGoogle Scholar
  14. 14.
    Hausenloy DJ, Yellon DM. (2013) Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 123:92–100.CrossRefGoogle Scholar
  15. 15.
    Kakinuma Y, et al. (2012) A non-neuronal cardiac cholinergic system plays a protective role in myocardium salvage during ischemic insults. PLoS One. 7:e50761.CrossRefGoogle Scholar
  16. 16.
    Kakinuma Y, Akiyama T, Sato T. (2009) Cholinoceptive and cholinergic properties of cardiomyocytes involving an amplification mechanism for vagal efferent effects in sparsely innervated ventricular myocardium. FEBS J. 276:5111–25.CrossRefGoogle Scholar
  17. 17.
    Kakinuma Y, et al. (2013) Heart-specific overexpression of choline acetyltransferase gene protects murine heart against ischemia through hypoxia-inducible factor-1alpha-related defense mechanisms. J. Am. Heart Assoc. 2:e004887.CrossRefGoogle Scholar
  18. 18.
    Katare RG, et al. (2009) Vagal nerve stimulation prevents reperfusion injury through inhibition of opening of mitochondrial permeability transition pore independent of the bradycardiac effect. J. Thorac. Cardiovasc. Surg. 137:223–31.CrossRefGoogle Scholar
  19. 19.
    Katzeff HL, Powell SR, Ojamaa K. (1997) Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. Am. J. Physiol. 273:E951–6.PubMedGoogle Scholar
  20. 20.
    Kawada T, et al. (2000) Differential acetylcholine release mechanisms in the ischemic and non-ischemic myocardium. J. Mol. Cell. Cardiol. 32:405–14.CrossRefGoogle Scholar
  21. 21.
    Kenessey A, Ojamaa K. (2006) Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J. Biol. Chem. 281:20666–72.CrossRefGoogle Scholar
  22. 22.
    Khan NS, et al. (2015) Cytosolic phospholipase A2alpha is critical for angiotensin II-induced hypertension and associated cardiovascular pathophysiology. Hypertension. 65:784–92.CrossRefGoogle Scholar
  23. 23.
    Koga K, et al. (2011) Macrophage migration inhibitory factor provides cardioprotection during ischemia/reperfusion by reducing oxidative stress. Antioxid. Redox. Signal. 14:1191–1202.CrossRefGoogle Scholar
  24. 24.
    LaCroix C, Freeling J, Giles A, Wess J, Li YF. (2008) Deficiency of M-2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress. Am. J. Physiol.-Heart C. 294: H810–20.CrossRefGoogle Scholar
  25. 25.
    Lara A, et al. (2010) Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure. Mol. Cell. Biol. 30:1746–56.CrossRefGoogle Scholar
  26. 26.
    Lataro RM, et al. (2013) Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305:R908–16.CrossRefGoogle Scholar
  27. 27.
    Li DL, et al. (2011) Acetylcholine inhibits hypoxia-induced tumor necrosis factor-alpha production via regulation of MAPKs phosphorylation in cardiomyocytes. J. Cell. Physiol. 226:1052–59.CrossRefGoogle Scholar
  28. 28.
    Lin X, et al. (2005) Macrophage migration inhibitory factor within the alveolar spaces induces changes in the heart during late experimental sepsis. Shock. 24:556–63.CrossRefGoogle Scholar
  29. 29.
    Lykhmus O, et al. (2014) Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction. Int. J. Biochem. Cell. Biol. 53:246–52.CrossRefGoogle Scholar
  30. 30.
    Murphy E, et al. (2016) Mitochondrial function, biology, and role in disease: a scientific statement from the American Heart Association. Circ. Res. 118:1960–91.CrossRefGoogle Scholar
  31. 31.
    Nordstrom P, Religa D, Wimo A, Winblad B, Eriksdotter M. (2013) The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer’s disease. Eur. Heart J. 34:2585–91.CrossRefGoogle Scholar
  32. 32.
    Okazaki Y, Zheng C, Li M, Sugimachi M. (2010) Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. J. Physiol. Sci. 60:67–74.CrossRefGoogle Scholar
  33. 33.
    Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. (2008) Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation. 118:863–71.CrossRefGoogle Scholar
  34. 34.
    Pavlov VA, Tracey KJ. (2012) The vagus nerve and the inflammatory reflex—linking immunity and metabolism. Nat. Rev. Endocrinol. 8:743–54.CrossRefGoogle Scholar
  35. 35.
    Rana OR, et al. (2010). Acetylcholine as an age-dependent non-neuronal source in the heart. Auton. Neurosci-Basic. 156:82–89.CrossRefGoogle Scholar
  36. 36.
    Rocha-Resende C, et al. (2012) Non-neuronal cholinergic machinery present in cardiomyocytes offsets hypertrophic signals. J. Mol. Cell. Cardiol. 53:206–16.CrossRefGoogle Scholar
  37. 37.
    Rocha JA, et al. (2016) Increase in cholinergic modulation with pyridostigmine induces anti-inflammatory cell recruitment soon after acute myocardial infarction in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 310:R697–706.CrossRefGoogle Scholar
  38. 38.
    Rosas-Ballina M, et al. (2011) Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science. 334:98–101.CrossRefGoogle Scholar
  39. 39.
    Roy A, et al. (2016) Cardiac acetylcholine inhibits ventricular remodeling and dysfunction under pathologic conditions. FASEB J. 30:688–701.CrossRefGoogle Scholar
  40. 40.
    Roy A, Guatimosim S, Prado VF, Gros R, Prado MAM. (2014) Cholinergic activity as a new target in diseases of the heart. Mol. Med. 20:527–37.Google Scholar
  41. 41.
    Rysevaite K, et al. (2011) Immunohistochemical characterization of the intrinsic cardiac neural plexus in whole-mount mouse heart preparations. Heart Rhythm. 8:731–38.CrossRefGoogle Scholar
  42. 42.
    Sabino JP, da Silva CA, de Melo RF, Fazan R Jr, Salgado HC. (2013) The treatment with pyridostigmine improves the cardiocirculatory function in rats with chronic heart failure. Auton. Neurosci. 173:58–64.CrossRefGoogle Scholar
  43. 43.
    Sadis C, et al. (2007) Nicotine protects kidney from renal ischemia/reperfusion injury through the cholinergic anti-inflammatory pathway. PloS One 2:e469.CrossRefGoogle Scholar
  44. 44.
    Samochocki M, et al. (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Therap. 305:1024–36.CrossRefGoogle Scholar
  45. 45.
    Schwartz PJ, De Ferrari GM. (2009) Vagal stimulation for heart failure: background and first in-man study. Heart Rhythm. 6:S76–81.CrossRefGoogle Scholar
  46. 46.
    Smedlund K, Tano JY, Margiotta J, Vazquez G. (2011) Evidence for operation of nicotinic and muscarinic acetylcholine receptor-dependent survival pathways in human coronary artery endothelial cells. J. Cell. Biochem. 112:1978–84.CrossRefGoogle Scholar
  47. 47.
    Wang H, et al. (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 421:384–88.CrossRefGoogle Scholar
  48. 48.
    Woodruff-Pak DS, Vogel RW 3rd, Wenk GL. (2001) Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc. Nat. Acad. Sci. U.S.A. 98:2089–94.CrossRefGoogle Scholar
  49. 49.
    Xiong J, et al. (2012) Postconditioning with alpha7nAChR agonist attenuates systemic inflammatory response to myocardial ischemia—reperfusion injury in rats. Inflammation. 35:1357–64.CrossRefGoogle Scholar
  50. 50.
    Xiong J, et al. (2012) Combined postconditioning with ischemia and alpha7nAChR agonist produces an enhanced protection against rat myocardial ischemia reperfusion injury. Chin. Med. J. (Engl.) 125:326–31.Google Scholar
  51. 51.
    Yeboah MM, et al. (2008) Cholinergic agonists attenuate renal ischemia-reperfusion injury in rats. Kidney Int. 74:62–69.CrossRefGoogle Scholar
  52. 52.
    Yeboah MM, Xue X, Javdan M, Susin M, Metz CN. (2008) Nicotinic acetylcholine receptor expression and regulation in the rat kidney after ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 295: F654–61.CrossRefGoogle Scholar
  53. 53.
    Zhang YH, et al. (2009) Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ-Heart Fail. 2:692–99.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Spyros A. Mavropoulos
    • 1
    • 4
  • Nayaab S. Khan
    • 1
  • Asaph C. J. Levy
    • 4
  • Bradley T. Faliks
    • 4
  • Cristina P. Sison
    • 2
    • 4
  • Valentin A. Pavlov
    • 3
    • 4
  • Youhua Zhang
    • 5
  • Kaie Ojamaa
    • 1
    • 4
    • 5
  1. 1.Center for Heart and Lung ResearchThe Feinstein Institute for Medical Research, Northwell HealthManhassetUSA
  2. 2.Biostatistics UnitThe Feinstein Institute for Medical Research, Northwell HealthManhassetUSA
  3. 3.Center for Biomedical SciencesThe Feinstein Institute for Medical Research, Northwell HealthManhassetUSA
  4. 4.Hofstra Northwell School of MedicineHofstra UniversityHempsteadUSA
  5. 5.Department of Biomedical SciencesNew York Institute of Technology College of Osteopathic MedicineOld WestburyUSA

Personalised recommendations